 Jennifer Shannon
Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urate Oxidase | 1 | 2012 | 9 | 0.410 |
Why?
| | Gout Suppressants | 1 | 2012 | 20 | 0.400 |
Why?
| | Gout | 1 | 2012 | 37 | 0.390 |
Why?
| | Enzymes, Immobilized | 1 | 2012 | 36 | 0.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 1361 | 0.290 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 576 | 0.280 |
Why?
| | Adenocarcinoma | 3 | 2016 | 799 | 0.200 |
Why?
| | ras Proteins | 1 | 2021 | 138 | 0.180 |
Why?
| | Pancreatic Neoplasms | 2 | 2019 | 722 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2021 | 192 | 0.170 |
Why?
| | Colorectal Neoplasms | 2 | 2021 | 617 | 0.170 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.160 |
Why?
| | Fluorouracil | 5 | 2021 | 151 | 0.160 |
Why?
| | Liver Neoplasms | 2 | 2016 | 521 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 577 | 0.150 |
Why?
| | Deoxycytidine | 2 | 2019 | 140 | 0.140 |
Why?
| | Pancreatectomy | 1 | 2019 | 169 | 0.140 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2019 | 208 | 0.140 |
Why?
| | Esophagogastric Junction | 1 | 2016 | 42 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 54 | 0.130 |
Why?
| | Stomach Neoplasms | 1 | 2016 | 66 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 863 | 0.120 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2013 | 12 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1893 | 0.110 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 83 | 0.110 |
Why?
| | Esophageal Neoplasms | 1 | 2016 | 273 | 0.100 |
Why?
| | Prognosis | 3 | 2021 | 3339 | 0.100 |
Why?
| | Mutation | 1 | 2021 | 3364 | 0.090 |
Why?
| | Health Expenditures | 1 | 2012 | 173 | 0.090 |
Why?
| | Leucovorin | 3 | 2019 | 42 | 0.090 |
Why?
| | Skin Neoplasms | 2 | 2009 | 761 | 0.090 |
Why?
| | Disease-Free Survival | 4 | 2016 | 621 | 0.080 |
Why?
| | Lymphatic Metastasis | 4 | 2016 | 276 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2007 | 182 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1048 | 0.070 |
Why?
| | Yttrium Radioisotopes | 1 | 2007 | 57 | 0.070 |
Why?
| | Brachytherapy | 1 | 2007 | 104 | 0.070 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2005 | 17 | 0.060 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 179 | 0.060 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2004 | 7 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 425 | 0.060 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2004 | 29 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2021 | 526 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2207 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 334 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.050 |
Why?
| | Aged | 6 | 2021 | 19250 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 249 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2016 | 9159 | 0.040 |
Why?
| | Risk Assessment | 1 | 2009 | 2987 | 0.040 |
Why?
| | Prospective Studies | 2 | 2021 | 6264 | 0.040 |
Why?
| | Humans | 9 | 2021 | 115589 | 0.040 |
Why?
| | Anorexia | 1 | 2016 | 18 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1216 | 0.030 |
Why?
| | Capecitabine | 1 | 2016 | 46 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1219 | 0.030 |
Why?
| | Taxoids | 1 | 2016 | 94 | 0.030 |
Why?
| | Nausea | 1 | 2016 | 103 | 0.030 |
Why?
| | Vomiting | 1 | 2016 | 125 | 0.030 |
Why?
| | Diarrhea | 1 | 2016 | 173 | 0.030 |
Why?
| | Male | 7 | 2021 | 55949 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 263 | 0.030 |
Why?
| | Fatigue | 1 | 2016 | 296 | 0.030 |
Why?
| | Middle Aged | 5 | 2016 | 26998 | 0.030 |
Why?
| | Europe | 1 | 2013 | 336 | 0.030 |
Why?
| | Female | 6 | 2021 | 59913 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4440 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 815 | 0.020 |
Why?
| | Animals | 1 | 2012 | 32102 | 0.020 |
Why?
| | Adult | 4 | 2016 | 30719 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 1265 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2007 | 40 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2007 | 37 | 0.020 |
Why?
| | Microspheres | 1 | 2007 | 122 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 182 | 0.020 |
Why?
| | United Kingdom | 1 | 2007 | 227 | 0.020 |
Why?
| | Australia | 1 | 2007 | 207 | 0.020 |
Why?
| | Recurrence | 1 | 2009 | 952 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 6417 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2007 | 187 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1805 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2004 | 286 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12608 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2005 | 1127 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1087 | 0.010 |
Why?
| | Survival Rate | 1 | 2005 | 1650 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1056 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2004 | 1357 | 0.010 |
Why?
| | Time Factors | 1 | 2007 | 6165 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 2392 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2004 | 3071 | 0.010 |
Why?
|
|
Shannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|